Table 4. Differences between demographic groups in the coverage of dose 1, timely dose 1, and series completion for Hib vaccine and PCV in Shanghai children, 2012.

	Hib vaccine dose 1	Hib vaccine series completiona	Hib vaccine timely dose 1b	PCV dose 1	PCV series completiona
	(n = 28,141)	(n = 14,316)	(n = 28,141)	(n = 28,141)	(n = 3,204)
Crude model
Floating vs. locals	−1.6%**	−10.0%**	−1.4%**	−5.6%**	0.4%**
Adjusted model 1
Floating vs. locals	−0.1%**	−9.0%**	−0.8%**	−5.0%**	−0.6%**
Suburban vs. urban	−7.2%**	0.0%**	−3.7%**	−3.4%**	2.6%**
2008–2010 vs. 2005–2007	4.5%**	−6.1%**	6.6%**	−2.5%**	−14.6%**
Adjusted model 2 c
Floating vs. locals	5.4%**	−5.0%**	−2.3%**	−1.9%**	−2.7%**
Suburban vs. urban	−3.0%**	2.5%**	−4.6%**	−0.8%**	1.6%**
Floating * suburban	−8.4%**	−6.1%**	1.9%**	−4.6%**	2.6%**
2008–2010 vs. 2005–2007	4.7%**	−5.9%**	6.6%**	−2.4%**	−14.6%**

Hib: Haemophilus influenzae type b; PCV: 7-valent pneumococcal conjugate vaccine.

*P<0.05, chi-square test from binomial regression with identity link.

**P<0.0001, chi-square test from binomial regression with identity link.

^aSeries completion was calculated for only those children with dose 1; variable constructed from manufacturers' recommendations.

^bTimeliness was constructed from manufacturers' recommendations.

^cThe likelihood ratio test comparing adjusted models 1 and 2 was not significant for the outcome “PCV series completion,” indicating that the fit did not improve with the addition of the interaction term.